Systematic review: patient‐centred endpoints in economic evaluations of gastro‐oesophageal reflux disease
Open Access
- 15 August 2002
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 16 (8) , 1469-1480
- https://doi.org/10.1046/j.1365-2036.2002.01303.x
Abstract
To perform a systematic review of the economic literature on gastro-oesophageal reflux disease to evaluate (a) the use of patient-centred effectiveness end-points, or (b) the use of patient-centred economic end-points, and the influence of these end-points on the outcome of the model. Three electronic databases (EMBASE, BIOSIS and Medline) were used, together with a manual search of meeting abstracts for relevant articles. The quality of the studies was determined by the Drummond criteria. Our initial search identified 179 articles and a manual search revealed 78 abstracts and articles. A total of 47 studies (36 fully published articles and 11 abstracts) met the seven Drummond criteria for inclusion in our evaluation. This systematic review demonstrates that many of the published economic evaluations available today take the perspective of the third-party payer and focus on pharmaceutical costs relevant to the third-party payer. Our study also demonstrates that there are a number of costs of illness determinations, such that pharmaceutical costs account for only a small proportion of the total costs of managing gastro-oesophageal reflux disease. Future economic analyses should consider an evaluation of the patient's desire for complete symptom relief by including cost-utility assessments or willingness to pay data.Keywords
This publication has 52 references indexed in Scilit:
- Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trialsClinical Therapeutics, 2001
- Willingness to pay for relief of gastroesophageal reflux diseaseGastroenterology, 2001
- Economic Evaluation of Long Term Management Strategies for Erosive OesophagitisPharmacoEconomics, 1999
- GIR1 Economic And Clinical Outcomes Models for the Evaluation of Drug Therapy Strategies in Treatment of GerdValue in Health, 1998
- Utilisation and Expenditures in the Treatment of Patients with Gastro-Oesophageal Reflux DiseaseDisease Management and Health Outcomes, 1998
- Omeprazole or Ranitidine Plus Metoclopramide for Patients with Severe Erosive OesophagitisPharmacoEconomics, 1995
- Economic Analysis of Alternative Treatments for Persistent Gastro-Oesophageal Reflux DiseaseScandinavian Journal of Gastroenterology, 1994
- Omeprazole vs Ranitidine in Reflux Oesophagitis in SwedenPharmacoEconomics, 1994
- Assessing the Cost-effectiveness of Medical Treatments in Acid-related Diseases: The Markov Chain Approach Applied to a Comparison between Intermittent and Maintenance Treatment of Reflux EsophagitisScandinavian Journal of Gastroenterology, 1993
- Economic Costs of Functional DyspepsiaPharmacoEconomics, 1992